GLPG1837 

Small molecule CFTR potentiator

Phase of research

Pre-clinical

How it helps

Restore CFTR Function

General information

GLPG1837 is an experimental substance used in studies and not yet available as a human pharmaceutical. In relation to cystic fibrosis, our AIM tool found the data that GLPG1837 can help potentiate G178R-, G551D-, S549N- and R117H-CFTR channels and also corrector-rescued F508del-CFTR.

GLPG1837 on PubChem

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

Structure not available

C16H20N4O3S

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
F508del
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 In combination with F508del correction.
G178R
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.
G551D
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.
R117H
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.
S549N
1 3.85
Link Tested on Impact factor Notes
Identification and Characterization of Novel CFTR Potentiators human cell cultures 3.85 Better than ivacaftor.

Does not treat

Mutation Number of sources Average impact factor